Le Lézard
Classified in: Health
Subjects: PDT, FDA, PLW

USPTO Grants Xenocor Fourth US Patent, Achieving Increased Protection for their Novel Saberscope System


SALT LAKE CITY, Aug. 17, 2022 /PRNewswire/ -- Xenocor, a Utah-based medical device company, today announced newly issued U.S. patent protection for the Saberscope system from the United States Patent and Trademark Office (USPTO). The Saberscope system is the world's first true HD, fog free, omnidirectional articulating, recyclable laparoscope.

"The Saberscope system is the world's first true HD, fog free, omnidirectional articulating, recyclable laparoscope."

With the Saberscope's innovative and disposable design, it sets itself apart from all other laparoscopes on the market today. All traditional laparoscopes present unnecessary patient risk, hassles, cost, workflow complexity and waste. Not only do they expose patients to potential cross contamination, they are also a leading source of OR fires and arc injuries. They provide inconsistent visualization due to aging components, fog and smoke and steam. They are all prone to fogging and have a limited visual field due to lack of articulation. They require substantial upfront capital costs. They require long setup procedures and complex logistics to be cleaned. Lastly, they produce significant waste in their cleaning process.

The Saberscope system addresses every one of these challenges. It is a disposable 5mm scope, so there is no risk of cross contamination. It is non-conducting and does not get hot enough to initiate combustion. It is brand new out of the box every time, is completely fog free and sees better through smoke and steam. It articulates to 90 degrees in every direction, requires little to no capital costs and requires no complex setup or sterilization logistics. Lastly, it is recyclable and creates less landfill and water waste than traditional scopes.

"Additional patent protection supports Xenocor's innovative design, assembly, system, utility, and use," said Charles DeCoster IV, Chief Executive Officer. "Xenocor's novel technology has the potential to significantly improve laparoscopic surgery and bring minimally invasive technology into the 21st century."

The Saberscope system is FDA cleared for use in laparoscopic and thoracoscopic surgery. Xenocor's devices have been used in over 300 live human cases.

Xenocor is a privately held company that designs, develops, and commercializes medical devices including the Saberscope system. Xenocor has 11 combined issued and pending U.S. and global patents.

www.XENOCOR.com

View product video here: https://vimeo.com/505004139

Live procedures footage here: https://vimeo.com/505743964

Xenocor contact: (844) 936-6267; [email protected].

SOURCE Xenocor, Inc.


These press releases may also interest you

at 18:15
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units...

at 18:07
A new guideline has been issued to help neurologists and other clinicians determine the best antiseizure medications for people with epilepsy who may become pregnant. The guideline is published in the May 15, 2024, online issue of Neurology®, the...

at 18:00
The leading cause of death worldwide is chronic inflammatory diseases. When the body is inflamed and under stress for long periods of time, the body's heart rate increases, increasing the risk of fatality. A new study published in Brain, Behavior and...

at 17:55
The global gas chromatography market  size is estimated to grow by USD 1042.59 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of  7.14%  during the forecast period. ...

at 17:50
Blue Cross Blue Shield of Michigan's Board of Directors today appointed Tricia A. Keith as president and CEO-Elect. Ms. Keith, 53, will succeed Daniel J. Loepp as president and CEO following his retirement on January 1, 2025. She will become the...

at 17:45
Quest Diagnostics , a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock...



News published on and distributed by: